Background: To elucidate the clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with axitinib. Methods: A total of 58 patients were retrospectively analyzed. All patients received axitinib treatment for mRCC at Keio University hospital in Japan. Baseline clinical factors and on treatment adverse events were assessed to predict survival. Results: The median progression free survival (PFS) for axitinib treatment was 10.9 months (95% CI 5.8-13.5), and the median overall survival (OS) from the start of axitinib treatment was 39.8 months (95% CI 25.9-NR), respectively. The PFS (P < 0.0001) and OS (P = 0.0022) were significantly correlated with the International mRCC Database Consortium (IMDC) classification, respectively. The PFS and OS were significantly longer in patients who received longer prior treatment (P = 0.0424 and 0.0067, respectively). On-treatment hypertension, hand foot syndrome and hypothyroidism were associated with longer PFS (P = 0.0002, 0.0055 and 0.0290, respectively). Ontreatment hypertension, diarrhea, and hand foot syndrome were associated with longer OS (P = 0.0004, 0.0036 and 0.0115, respectively). Conclusions: Baseline and on treatment factors are identified as prognostic markers in mRCC patients treated with axitinib. Our findings might be helpful for clinicians to select the best treatment to individual patients.
Introduction
With the widespread use of molecular targeted drugs, systemic management for metastatic renal cell carcinoma (mRCC) has been changing dramatically over the past 10 years. Anti-angiogenic agents targeting vascular endothelial growth factor (VEGF) and inhibitors of mammalian target of rapamycin (mTOR) replaced cytokine based therapies. Currently recommended anti-VEGF treatment for previously untreated patients include the oral, multi-target, tyrosine kinase inhibitors (TKIs), namely sunitinib and pazopanib. The treatment approach for patients with mRCC consisted of sequential use of VEGF TKIs or mTOR inhibitors. The National Comprehensive Cancer Network (NCCN) guidelines have suggested everolimus and axitinib for second-line treatment of mRCC with category 1 evidence after firstline VEGF targeted treatment (1). However, based on the CheckMate025 and METEOR trials, the programmed cell death 1 (PD-1) antibody nivolumab and the MET/VEGFR/AXL inhibitor cabozantinib, which demonstrated comparable progression free survival (PFS) and overall survival (OS), have obtained category 1 recommendations as second-line treatment (1-3). Given the variety of available therapeutic agents which target different pathways, research is now ongoing to elucidate appropriate sequencing and combinations of the drugs for the treatment of mRCC.
Axitinib (AG-013736), a second-generation, selective TKI of the VEGF receptor (VEGFR-1, 2, and 3) have obtained approval by the US Food and Drug Administration (FDA) in 2012 as a second-line option for the treatment of patients with advanced RCC. In the AXIS Phase III trial, axitinib has achieved significant improvements in PFS compared with sorafenib treatment arm as second-line treatment (4). Thus axitinib has been extensively used for patients who progressed after first-line systemic therapy; however, long-term control of mRCC still remains challenging due to development of drug resistance. Identification of patients who might benefit from axitinib treatment has been warranted. The aim of this study is to find key clinical factors to predict survival in mRCC patients treated with axitinib.
Patients and methods
Between 2010 and 2017, 151 patients with mRCC received treatment with molecular targeted agents at Keio University Hospital. After receiving approval from our institutional review board (Approval No 2013-0425), we retrospectively analyzed 58 patients who received axitinib treatment. Disease and patient assessment at baseline included performance status, radiological examination with computed tomography (CT) and blood test. All cases were grouped into three different categories (favorable risk group (Fav), intermediate risk group (Int) and poor risk group (Por)) based on the International mRCC Database Consortium (IMDC) risk classification prior to administration of first-line drug (5).
During axitinib treatment, patients were followed up every 2-4 weeks with routine physical exams and laboratory tests. Chestabdomen-pelvis CT examinations were routinely scheduled every 3-4 months, while elective brain CT or bone scintigraphy were scheduled only when clinically indicated. The Kaplan-Meier methodology was utilized to calculate median survival with statistical significance being determined by the log-rank test. Treatment-induced toxicities graded in Common Terminology Criteria for Adverse Events (CTCAE) ver 4.0 during axitinib treatment, age, prior therapy duration and baseline MSKCC risk groups were analyzed to predict survival (6) . We used Statistical Package for Social Sciences (SPSS) version 23.0 for all analyses.
Results

Patient characteristics
The study group comprised 58 patients. The patient characteristics are summarized in Table 1 . The median follow-up time was 25 months (range 1-81 months). In total, axitinib was given as firstline treatment in 5 (8.6%) mRCC patients, and second line in 35 (60.3%), and third or later line in 18 (31.1%), respectively. Of those patients who received axitinib as second line, 9 (25.7%) received cytokine, and 24 (68.6%) received VEGFR-TKI, and 2 (5.7%) received temsirolimus in first-line treatment.
Efficacy
Three (5.2%) and 11 (19.0%) patients achieved a complete response (CR) and partial response (PR), respectively. Twenty-eight (48.3%) patients presented with stable disease (SD), whereas eight patients (13.8%) showed progressive disease (PD). Seven patients were considered not assessable for efficacy. The objective response rate (ORR; CR + PR) were 24.2%. The median PFS for axitinib treatment was 10.9 months (95% CI 5.8-13.5) (Fig. 1A) , and the median OS from the start of axitinib treatment was 39.8 months (95% confidence interval (CI) 25.9 -not reached (NR)) (Fig. 1B) , respectively.
Safety
The adverse event (AE) recorded in more than half of our cohort was hypertension, proteinuria and hypothyroidism (Table 2) . Treatment-related Grade ≥3 AE included hypertension, proteinuria, diarrhea, chronic kidney disease, GI bleeding, GI perforation and hypoglycemia (Table 2 ). There were no statistical differences in toxicity profiles, when axitinib was used as second-or further-line therapy (data not shown). One patient experienced Grade 4 AE (chronic kidney disease). Since we experienced Grade 4 AE, we evaluated the changes in serum creatinine (s-Cr) levels and estimated glomerular filtration rate (eGFR) during axitinib treatment. During axitinib treatment, neither significant increase in mean s-Cr (from 1.13 to 1.26 mg/dl; P = 0.1370) nor decrease in mean eGFR (from 54.2 to 53.4 ml/min/1.73 m 2 ; P = 0.5752) was observed, respectively.
Predictors of survival
Using the baseline clinical factors for the IMDC risk stratification, 13 (22.4%), 32 (55.2%) and 13 (22.4%) patients were grouped into Fav, Int and Por, respectively. Estimated median PFS of axitinib treatment for Fav, Int and Por was 27.9 months (95% CI 11.0-34.6), 19.6 months (95% CI 10.9-42.4) and 4.1 months (95% CI 0.8-7.9), respectively (log rank P < 0.0001, Fig. 2A ). Estimated median OS from the initiation of axitinib treatment in each risk group was 51.7 months (Fav; 95% CI 22.5-NR), 65.2 months (Int; 95% CI 24.9-NR) and 12.2 months (Por; 95% CI 0.9-29.9), respectively (log rank P = 0.0022, Fig. 2B ). There were no differences in PFS (P = 0.1821) and OS (P = 0.1469) between the old group (age ≥75 years) and the younger group (age <75 years). We dichotomized duration of prior therapy by 1 year because median PFS for first-line therapy was 1 year. The PFS and OS were significantly longer in patients who received longer prior treatment (P = 0.0424 and 0.0067, respectively, Fig. 3A and B) . Common AEs during axitinib treatment, namely hypertension, proteinuria, diarrhea, hand foot syndrome and hypothyroidism were chosen as predictors of survival. On-treatment hypertension, hand foot syndrome and hypothyroidism were associated with longer PFS (P = 0.0002, 0.0055 and 0.0290, respectively). On-treatment hypertension, diarrhea and hand foot syndrome were associated with longer OS (P = 0.0004, 0.0036 and 0.0115, respectively).
Discussion
The AXIS trial, which randomized 723 patients with mRCC to axitinib or sorafenib in the second-line setting, demonstrated a median PFS of 6.7 months for axitinib versus 4.7 months for sorafenib (4) . In the Japanese subgroup analysis of this Phase 3 trial, the median PFS achieved in axitinib arm were reported to be longer compared with those achieved in the overall population (7). In our cohort, the median PFS and OS were estimated longer compared with historical cohorts, and toxicities with long-term axitinib treatment were generally manageable. Thus it seems worthwhile to treat previously treated mRCC patients with axitinib, although multiple second-line treatment option exists. In addition, there were no statistical differences in survival data (including PFS and OS), and toxicity profiles when axitinib was used as second-or further-line treatment, which implied the potential of axitinib as a late line treatment option.
Common AEs observed in our cohort during treatment with axitinib were generally comparable to those reported in AXIS study and its Japanese subgroup (4,7). Furthermore, those patients presented with several AEs, such as hypertension, hand foot syndrome and diarrhea, showed better survival when compared with their counterparts. As previously hypothesized (8), these AEs would be correlated with intended target inhibition of axitinib. For example, the susceptibility of blood vessels to VEGF inhibition, resulting in hypertension, may also be linked to the susceptibility of tumor vessels to VEGF inhibition, providing a biological underpinning for efficacy. Previous studies have investigated hypertension as a predictive biomarker of the effectiveness of anti-angiogenic therapy (9) . Retrospective analyses evaluating the relationship between hypertension and outcome in cases treated with sunitinib, bevacizumab or sorafenib report a similar relationship to that observed here for axitinib (10) (11) (12) (13) . In addition, recent Phase 2 dose titration study demonstrated that higher plasma concentration of axitinib might be correlated with its efficacy as well as incidence of severe AEs, suggesting plasma concentration as a predictor of axitinib (14) . The prognostic value of on-treatment hypertension, hand foot syndrome and diarrhea seems promising; however, unfortunately on treatment AEs have little impact on drug choice in the second-line setting. Therefore, we further evaluated baseline characteristics as prognostic indices of axitinib treatment and found that patients in Fav-Int or patients who received longer prior treatment demonstrated better survival. One possible explanation is mechanism of action of 
axitinib, which blocks VEGF receptor and inhibits tumor angiogenesis. It is not surprising if axitinib is not effective to those patients with intrinsic or acquired resistance to VEGF targeted drugs. In other words, cases with VEGF targeted drug resistance, such as patients in poor risk group or with poor response to prior treatment, would not receive benefit from axitinib treatment. Because targeted therapies are rarely curative and often result in resistance or intolerance, sequential regimens of these agents are commonly used and are recommended in current treatment guidelines. To date, four regimens (nivolumab, cabozantinib, axitinib, everolimus plus lenvatinib) have category 1 recommendations for post TKI treatment (1), however, clinicians often face difficult decisions about choice of post TKI treatment drugs to treat mRCC effectively because head-to-head comparison of those agents are lacking. When experimental trial data are lacking, real world data can provide context around patterns of care. Our study demonstrated the efficacy of axitinib in the treatment of patients in Fav-Int or in those with longer prior therapy duration. Those patients might be still susceptive to VEGF targeted therapy after prior therapy and therefore continuing anti-VEGF therapy with axitinib showed better PFS. On the other hand, axitinib did not show efficacy in patients with poor risk features or in patients with shorter prior therapy duration. For patients with poor risk features, temsirolimus significantly prolonged OS and has been recommended for first-line treatment, however, median OS is still 4.8 months and unmet need still exists for the treatment of patients in poor risk group (15) . Recently, subgroup analysis of CheckMate 025 Phase 3 trial revealed that patients in poor risk group could benefit from treatment with nivolumab rather than everolimus (16) . Although any cross-study comparison must be interpreted with caution, immuno-oncology drug might be an alternative strategy to treat patients in poor risk group. The mechanism why immuno-oncology drug is effective for mRCC still remains unclear. Immuno-oncology drug is known to be more effective in patients with higher mutational load, however, in mRCC, mutational load did not correlate with Memorial SloanKettering Cancer Center risk classification (17) . Future studies will reveal the exact mechanisms. Our study has several limitations. The retrospective design and relatively small number of patients are well known biases. Nevertheless, our study identified several factors which were associated with prolonged survival after axitinib treatment. Therefore, our findings might be helpful for clinicians to select the best treatment to individual patients.
In conclusion, axitinib demonstrated improved oncological outcomes and an acceptable safety profile for the second-and third-or later-line therapy for mRCC. Patients in Fav-Int, or with good response to prior treatment, could be good candidates for axitinib treatment. 
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